Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults


  • Philip Rosenthal M.D.

    Corresponding author
    1. Pediatric Liver Transplant Program, University of California, San Francisco, CA
    • University of California San Francisco, 500 Parnassus Ave., Box 0136, MU4-East, San Francisco, CA 94143-0136. Fax: 415-476-1343
    Search for more papers by this author

  • Dr. Rosenthal chairs the American Liver Foundation's Hepatitis A Vaccine Initiative. He has testified on behalf of Hepatitis A Vaccine legislation before the California, Nevada, and New Mexico State Assembly and Senate Health Committees. He is a Consultant to GlaxoSmithKline, one of the hepatitis A vaccine manufacturers.


Hepatitis A is a major public health problem in the United States and other developed countries, largely because decreased natural immunity allows for increased susceptibility. To evaluate the cost-effectiveness of routine vaccination of children, adolescents, and certain high-risk adults against hepatitis A, economic analyses of hepatitis A vaccination were identified through searches of MEDLINE, EMBASE, and BIOSIS (February, 1992, to December, 2001) for studies, reviews, editorials, and letters from peer-reviewed journals published in English, French, German, Italian, or Spanish. Experts were also contacted. Articles conforming to accepted standards of quality for health-economic studies were used to compile data on vaccination of children, and results were synthesized in a narrative review. This review of economic analyses of vaccine use in several developed countries shows cost-effectiveness comparable with that of other vaccines in children and within accepted boundaries for adolescents and high-risk adults.